The oncology market is projected to be one of the fastest growing segments in phamraceuticals. New treatments for oncology increasing include the use of high-potent APIs and antibody-drug conjugates.
Baxter BioPharma Solutions has announced (PBR) completion of its third expansion of its Halle, Germany manufacturing site. This course added 50% to its capacity for commercial cytotoxic manufacturing and also large scale lyophilization capability. Their filling process uses cRABS(closed Restricted Access Barrier System) to enchance safety for operators and increase product sterility protection.
Baxter also added capability to do cytotoxic emulsions, liposomes and suspensions, along with a nanoparticle suite equipped with a high pressure homogenizer. The company feels it is now well positioned to support customer oncology projects from small scale development through commercial scale at one location.
If you have been paying attention, you will have notice a lot of market activity with regard to bringing on new capacity for the manufacture of high-potency cytotoxics and antibody drug conjugates. SAFC has upgraded it facility in Madison, WI as well as opened new facilities in St. Louis and in Verona, WI. Several companies in India have also brought on new capacity this year or begun new capacity construction. Again, this speaks to the expected growth of the oncology space.
Posted by Bruce Lehr April 20th 2010.
Comments